期刊文献+

氨氯地平联合瑞舒伐他汀治疗冠心病合并高血压的疗效及安全性分析 被引量:7

下载PDF
导出
摘要 目的:分析针对冠心病伴高血压患者以氨氯地平、瑞舒伐他汀联合用药治疗的临床效果与安全性。方法:选择患冠心病伴高血压的60例患者,随机分成两组:参考组共30例,单以氨氯地平用药;研究组共30例,在参考组基础上联合氨氯地平用药治疗。治疗完毕后评估及比较两组的疗效,且观察患者用药后的不良反应发生情况。结果:与参考组开展对照分析发现,研究组经治疗后的有效率更高,差异显著(P<0.05)。研究组治疗后的LVEF、E/A与治疗前、参考组相比显著更高,LVEDD显著更低(P<0.05)。结论:冠心病伴高血压患者以氨氯地平、瑞舒伐他汀联合用药治疗可获良好的疗效,有助于促进心功能的改善,安全性高,值得借鉴。
作者 杜丞禹
出处 《影像研究与医学应用》 2017年第11期179-180,共2页 Journal of Imaging Research and Medical Applications
  • 相关文献

二级参考文献33

  • 1陈新石.高血压患者控制高血压同时降低胆固醇(联合使用络活喜和立普妥)可降低冠心病死亡和心肌梗死发作的风险[J].中华医学杂志,2007,87(10):717-717. 被引量:23
  • 2中国高血压防治指南修订委员会.中国高血压防治指南(第三版)2010年修订版[J].中华高血压杂志,2011,19(8):721-722.
  • 3Czemichow S, Zanchetti A, Turnbull F , et at. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major car?diovascular events according to baseline blood pressure: meta-analysis of randomized trials(J). J Hypertens ,2011 ;29(1) :4-16.
  • 4Conroy RM, Pyooraalaa K, Fitzgerald AP , et at. Estimation of ten -year risk of fatal cardiovascular disease in Europe: the SCORE project[J] . Eur Heart J ,2003 ;24(11) :987-1003.
  • 5De Backer G, Petrella JR, Goudev AR, et at. Design and methodology of POWER, an open-label observation of the effect of primary care interven- tions on total cardiovascular risk in patients with hypertension[J]. Fun?dam Clin Phannacol,2013;27(2) :210-5.
  • 6Turnbull F. Blood pressure lowering treatment trialists' collaboration. Effects of differentblo,?d-pressure-Iowering regimens on major cardiovas?cular events: results of prospectively designed overviews of randomised trialsj J]. Lancet ,2003 ;362(9395) : 1527 -35.
  • 7Ambrosioni E, Bombelli M, Cerasola G, et al. Ambulatory monitoring of systolic hypertension in the elderly: eprosartanlhydrochlorothiazide com?pared with losartanlhydrochlorothiazide(INSIST trial)[J] . Adv Ther, 2010 ;27(6) :365-80.
  • 8Guallar E, Banegas JR, Blasco-Colmenares E, et at. Excess risk attributa?ble to traditional cardiovascular risk factors in clinical practice settings across Europe The EURIKA Study[J] . BMC Public Health, 2011 ; 11 : 704.
  • 9Xu FY , Yang B, Shi D, et al. Antihypertensive effects and safety of epro?sartan: a meta-analysis of randomized controlled trials[J] . Eur J Clin Phannacol,2012;68(2) :195-205.
  • 10Baumhalikel M, Boohm M. Cardiovascular outcomes with angiotensin II receptor blockers: clinical implications of recent trials[J] . Vase Health Risk Manag,2011 ;7 :391-7.

共引文献318

同被引文献47

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部